drugset
Drugs / PEGylated recombinant human interferon alpha-2b
last change Jul 2023 re-read 3 minutes ago

PEGylated recombinant human interferon alpha-2b

Developed for
chronic hepatitis B virus infection
Investigated by
Anhui Medical University · Chaohu Hospital of Anhui Medical University · The First Affiliated Hospital of Bengbu Medical University · The First Affiliated Hospital, University of Science and Technology of China · The Second Hospital of Anhui Medical University

Trials 1

today NCT05922306 · Ph 0
2024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT05922306 Jul 2023 → Jun 2027 expected chronic hepatitis B virus infection Anhui Medical University Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as PEGylated recombinant human interferon alpha-2b ClinicalTrials.gov intervention name — accepted as the source's own label NCT05922306 ↗
Route Subcutaneous “administered by subcutaneous injection” NCT05922306 ↗